Last reviewed · How we verify

quadratus without triamcinolone. — Competitive Intelligence Brief

quadratus without triamcinolone. (quadratus without triamcinolone.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Pain management.

marketed NSAID COX enzymes Pain management Small molecule Live · refreshed every 30 min

Target snapshot

quadratus without triamcinolone. (quadratus without triamcinolone.) — Hospital de Braga. Quadratus is a medication that works by inhibiting the activity of certain enzymes in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
quadratus without triamcinolone. TARGET quadratus without triamcinolone. Hospital de Braga marketed NSAID COX enzymes
PCM/Oxy2 PCM/Oxy2 Maastricht University Medical Center marketed Opioid analgesic combination Mu opioid receptor (oxycodone); COX enzymes (paracetamol)
Acetaminophen/Codeine Acetaminophen/Codeine University of Pennsylvania marketed Opioid analgesic combination Mu opioid receptor (codeine); COX enzymes (acetaminophen)
Codeine/acetaminophen Codeine/acetaminophen Montefiore Medical Center marketed Opioid analgesic combination Mu-opioid receptor (codeine); COX enzymes (acetaminophen)
PCM/Oxy1 PCM/Oxy1 Maastricht University Medical Center marketed Opioid analgesic combination Mu opioid receptor (oxycodone); COX enzymes (paracetamol)
paracetamol codein paracetamol codein Diskapi Yildirim Beyazit Education and Research Hospital marketed Analgesic combination (paracetamol + opioid) COX enzymes (paracetamol); mu opioid receptor (codeine)
Codeine with acetaminophen Codeine with acetaminophen Children's Hospitals and Clinics of Minnesota marketed Opioid analgesic combination Mu opioid receptor (codeine); COX enzymes (acetaminophen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID class)

  1. Antibe Therapeutics Inc. · 3 drugs in this class
  2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
  3. Organon and Co · 2 drugs in this class
  4. Apsen Farmaceutica S.A. · 2 drugs in this class
  5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
  6. Behar, Caren, M.D. · 2 drugs in this class
  7. IDEA AG · 2 drugs in this class
  8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
  9. HALEON · 2 drugs in this class
  10. Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). quadratus without triamcinolone. — Competitive Intelligence Brief. https://druglandscape.com/ci/quadratus-without-triamcinolone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: